AMRI (NASDAQ: AMRI) announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE